Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Kodiak Sciences Inc (KOD) today and set a price target of $35.00. The company’s shares closed last Monday at $17.64, close to its 52-week high of $18.62.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 15.5% and a 47.9% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Applied Genetic Technologies, and Catalyst Biosciences Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Kodiak Sciences Inc with a $35.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.62 and a one-year low of $5.65. Currently, Kodiak Sciences Inc has an average volume of 174.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
